These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36057746)

  • 1. The Relative Contributions of NIH and Private Sector Funding to the Approval of New Biopharmaceuticals.
    Schulthess D; Bowen HP; Popovian R; Gassull D; Zhang A; Hammang J
    Ther Innov Regul Sci; 2023 Jan; 57(1):160-169. PubMed ID: 36057746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NIH funding for patents that contribute to market exclusivity of drugs approved 2010-2019 and the public interest protections of Bayh-Dole.
    Ledley FD; Cleary EG
    PLoS One; 2023; 18(7):e0288447. PubMed ID: 37494368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019.
    Galkina Cleary E; Jackson MJ; Zhou EW; Ledley FD
    JAMA Health Forum; 2023 Apr; 4(4):e230511. PubMed ID: 37115539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introducing new contraceptives.
    Segal SJ; Coutinho E
    Draper Fund Rep; 1986 Dec; (15):27-32. PubMed ID: 12341234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules.
    Azoulay P; Li D; Zivin JSG; Sampat BN
    Rev Econ Stud; 2019 Jan; 86(1):117-152. PubMed ID: 31662587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
    Darrow JJ; Avorn J; Kesselheim AS
    JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anatomy of medical research: US and international comparisons.
    Moses H; Matheson DH; Cairns-Smith S; George BP; Palisch C; Dorsey ER
    JAMA; 2015 Jan; 313(2):174-89. PubMed ID: 25585329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Public sector financial support for late stage discovery of new drugs in the United States: cohort study.
    Nayak RK; Avorn J; Kesselheim AS
    BMJ; 2019 Oct; 367():l5766. PubMed ID: 31645328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Citations in Life Science Patents to Publicly Funded Research at Academic Medical Centers.
    Sampat BN; Pincus HA
    Clin Transl Sci; 2015 Dec; 8(6):759-63. PubMed ID: 26728947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How much do the public sector and the private sector contribute to biopharmaceutical R&D?
    Simoens S; Huys I
    Drug Discov Today; 2022 Apr; 27(4):939-945. PubMed ID: 34863932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017.
    Skydel JJ; Egilman AC; Wallach JD; Ramachandran R; Gupta R; Ross JS
    JAMA Health Forum; 2022 May; 3(5):e221158. PubMed ID: 35977252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration.
    Hutchinson N; Carlisle B; Doussau A; Bosan R; Gumnit E; MacPherson A; Fergusson DA; Kimmelman J
    JAMA Netw Open; 2021 May; 4(5):e2110456. PubMed ID: 34003270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval.
    Cherla A; Naci H; Kesselheim AS; Gyawali B; Mossialos E
    JAMA Intern Med; 2021 Apr; 181(4):490-498. PubMed ID: 33616607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do March-In Rights Ensure Access to Medical Products Arising From Federally Funded Research? A Qualitative Study.
    Treasure CL; Avorn J; Kesselheim AS
    Milbank Q; 2015 Dec; 93(4):761-87. PubMed ID: 26626985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.
    Lythgoe MP; Desai A; Gyawali B; Savage P; Krell J; Warner JL; Khaki AR
    JAMA Netw Open; 2022 Jun; 5(6):e2216183. PubMed ID: 35687337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NIIMBL-Facilitated Active Listening Meeting between Industry and FDA Identifies Common Challenges for Adoption of New Biopharmaceutical Manufacturing Technologies.
    Mantle JL; Lee KH
    PDA J Pharm Sci Technol; 2020; 74(5):497-508. PubMed ID: 32467179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development.
    Miller KL; Mueller C; Liu G; Miller Needleman KI; Maynard J
    Orphanet J Rare Dis; 2020 Sep; 15(1):234. PubMed ID: 32883327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.